Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Celgene: Open-label Touchstone extension study showed symptom improvement

Celgene International Sarl announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at the United European Gastroenterology Week in Vienna, Austria and at the American College of Gastroenterology Annual Scientific Meeting in Las Vegas. Ozanimod is an investigational selective S1P 1 and 5 receptor modulator. TOUCHSTONE evaluated the efficacy and safety of 0.5 mg and 1 mg doses of ozanimod compared with placebo after eight weeks of treatment in 197 patients with moderate to severe active ulcerative colitis. Patients who achieved a clinical response at week 8 continued with their original treatment through week 32 in a maintenance phase. The primary endpoint was the proportion of patients in remission at week 8. Secondary endpoints were: the proportion of patients achieving a clinical response, the proportion of patients with mucosal improvement and the change from baseline in Mayo score. Previously reported results showed TOUCHSTONE met its primary endpoint and secondary endpoints with statistical significance for patients on the 1 mg dose of ozanimod versus placebo. TOUCHSTONE participants in all three treatment arms entered the open-label extension if they did not respond to treatment after the induction phase, relapsed during the maintenance phase or completed the maintenance phase The objective of the open-label extension phase is to evaluate the long-term efficacy and safety of daily ozanimod 1 mg. Treatment with ozanimod 1 mg in the extension phase also showed a decrease in the proportion of patients with rectal bleeding and moderate or severe diarrhea. "Findings from this extension study at week 44 showed improvements in efficacy measures for patients who took ozanimod throughout both the blinded study and the extension," said Scott Smith, President, Celgene Inflammation & Immunology. "We recognize the strong need for innovative treatments that help patients with inflammatory bowel disease achieve durable results. We are committed to advancing additional transformational oral treatment options for these patients."

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

WP

Worldpay

$78.73

-0.35 (-0.44%)

04:57
01/22/18
01/22
04:57
01/22/18
04:57
Recommendations
Worldpay analyst commentary  »

Worldpay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$46.93

0.46 (0.99%)

, QGEN

Qiagen

$32.87

0.31 (0.95%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Recommendations
Quidel, Qiagen analyst commentary  »

Quidel price target…

QDEL

Quidel

$46.93

0.46 (0.99%)

QGEN

Qiagen

$32.87

0.31 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

MCO

Moody's

$159.18

1.6 (1.02%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

SANM

Sanmina

$35.45

0.5 (1.43%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

JAGX

Jaguar Health

$0.16

-0.0169 (-9.83%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

$29.40

-0.16 (-0.54%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

BNED

Barnes & Noble Education

$7.70

0.25 (3.36%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

LLEX

Lilis Energy

$4.99

-0.12 (-2.35%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Lilis Energy management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 31

    Jan

NAVG

Navigators

$49.65

0.4 (0.81%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Navigators management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 16

    Feb

PETS

PetMed Express

$53.24

2.67 (5.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

December Chicago Fed…

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

ADP

ADP

$121.44

0.54 (0.45%)

, CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Stephens enterprise software analyst holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$121.44

0.54 (0.45%)

CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

ORCL

Oracle

$50.58

0.35 (0.70%)

PAYC

Paycom

$91.19

2.07 (2.32%)

PCTY

Paylocity

$49.99

0.33 (0.66%)

SAP

SAP

$113.20

1.53 (1.37%)

ULTI

Ultimate Software

$227.99

-0.84 (-0.37%)

WDAY

Workday

$114.11

0.83 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

IVC

Invacare

$16.91

0.26 (1.56%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 08

    Feb

PAYC

Paycom

$91.19

2.07 (2.32%)

, ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

$91.19

2.07 (2.32%)

ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

CA

CA Technologies

$34.07

-0.12 (-0.35%)

RHT

Red Hat

$125.94

0.47 (0.37%)

ORCL

Oracle

$50.58

0.35 (0.70%)

SSNC

SS&C

$49.98

0.04 (0.08%)

VMW

VMware

$136.04

0.41 (0.30%)

CTXS

Citrix

$92.72

1.34 (1.47%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

SYMC

Symantec

$27.46

0.21 (0.77%)

PANW

Palo Alto Networks

$157.22

-0.6 (-0.38%)

APTI

Apptio

$24.79

0.56 (2.31%)

CHKP

Check Point

$104.48

1.28 (1.24%)

NICE

Nice

$93.60

-0.23 (-0.25%)

SPLK

Splunk

$89.94

-1.49 (-1.63%)

RNG

RingCentral

$54.15

0.95 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

HAL

Halliburton

$53.01

0.65 (1.24%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: Halliburton has a potential bullish pattern »

There is a potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HPQ

HP Inc.

$23.70

0.41 (1.76%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

KMG

KMG Chemicals

04:52
01/22/18
01/22
04:52
01/22/18
04:52
Initiation
KMG Chemicals initiated  »

KMG Chemicals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 16

    Feb

KCDMY

Kimberly-Clark de Mexico

$9.44

0.05 (0.53%)

04:51
01/22/18
01/22
04:51
01/22/18
04:51
Downgrade
Kimberly-Clark de Mexico rating change  »

Kimberly-Clark de Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, SNY

Sanofi

$44.60

0.09 (0.20%)

04:49
01/22/18
01/22
04:49
01/22/18
04:49
Hot Stocks
Sanofi acquires Bioverativ for $105 per share in cash, or $11.6B »

Sanofi (SNY) and…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

SNY

Sanofi

$44.60

0.09 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

04:35
01/22/18
01/22
04:35
01/22/18
04:35
General news
FX Action: USD-JPY has ebbed back »

FX Action: USD-JPY has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.